Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print      Mail a friend       Annual reports

Thursday 21 June, 2018

Alliance Pharma PLC

Completion of Acquisition and TVR

RNS Number : 1937S
Alliance Pharma PLC
21 June 2018

                                                                                                                                                                21 June 2018

Alliance Pharma plc 

("Alliance" or the "Group")

Completion of Acquisition and Total Voting Rights

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that following today's admission of 37,362,638 new ordinary shares, it has completed the acquisition of the Nizoral Rights. This follows the announcements made by the Company on 19 June 2018 in relation to the Acquisition and Placing.

The Company now has a total of 514,205,522 ordinary shares in issue. The figure of 514,205,522 ordinary shares should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company released at 7.00 a.m. BST on 19 June 2018.


For further information:

Alliance Pharma plc

Tel:  +44 (0) 1249 466 966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

Numis Securities Limited

Tel:  +44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland

Corporate Broking: James Black

Investec Bank plc

Tel:  +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

Corporate Broking: Patrick Robb / David Herring


Tel:  +44 (0) 20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

[email protected]


Notes to editors


Alliance Pharma plc is an international specialty pharmaceutical company.

Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t